Carlos Eduardo
De Andrea
Profesor Titular
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (9)
2024
2023
-
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
Nature Medicine, Vol. 29, Núm. 6, pp. 1370-1378
-
Reference standards for gene fusion molecular assays on cytological samples: an international validation study
Journal of clinical pathology, Vol. 76, Núm. 1, pp. 47-52
2022
-
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
JCI Insight, Vol. 7, Núm. 7
-
Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481
2021
-
Delta-24-RGD, an oncolytic adenovirus, increases survival and promotes proinflammatory immune landscape remodeling in models of AT/RT and CNS-PNET
Clinical Cancer Research, Vol. 27, Núm. 6, pp. 1807-1820
2019
-
Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens
Cancer Cytopathology, Vol. 127, Núm. 5, pp. 285-296
-
Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients
Journal of Clinical Medicine, Vol. 8, Núm. 12
2017
-
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens
Cancer Cytopathology, Vol. 125, Núm. 8, pp. 615-626